Ginsenoside Rh2

CAS No. 78214-33-2

Ginsenoside Rh2( Ginsenoside Rh2 | HY-N0605 | HY N0605 )

Catalog No. M19102 CAS No. 78214-33-2

Ginsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 57 In Stock
5MG 30 In Stock
10MG 41 In Stock
25MG 65 In Stock
50MG 100 In Stock
100MG 158 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ginsenoside Rh2
  • Note
    Research use only, not for human use.
  • Brief Description
    Ginsenoside Rh2, an extract of red Panax ginseng, is a potent anti-inflammatory and anticancer drug.
  • Description
    Ginsenoside Rh2 is an aldose reductase inhibitor found in Panax. It also decreases ROS levels in keratinocytes, lowers levels of amyloid-β in Alzheimer's disease models, induces β-cell proliferation, inhibits osteoclastogenesis by suppressing RANKL-induced osteoclast differentiation.(In Vitro):Ginsenoside Rh2 induces the activation of two initiator caspases, caspase-8 and caspase-9 in human cancer cells. Ginsenoside Rh2 induces cancer cell apoptosis in a multi-path manner and is therefore a promising candidate for anti-tumor drug development. Ginsenoside Rh2 triggers p53-dependent Fas expression and consequent activation of caspase-8 and p53-independent caspase-9-mediated intrinsic pathway to cause cancer cell death.The cytotoxic activity of Ginsenoside Rh2 in the human tumor cell lines HeLa, SK-HEP-1, SW480, and PC-3 is assessed by MTT. The cell viability of HeLa cells is remarkably inhibited by Ginsenoside Rh2, with an IC50 value of 2.52 μg/mL, whereas SK-HEP-1 and SW480 cells are less sensitive to Ginsenoside Rh2, with IC50 values of 3.15 μg/mL and 4.06 μg/mL, respectively. PC-3 cells are the least vulnerable to Ginsenoside Rh2, with an IC50 value of 7.85 μg/mL, 3-fold higher than HeLa cells.(In Vivo):A total of 15 days following B16-F10 cell injection, tumor sizes from the 3 tumor bearing groups are measured. The tumor sizes in the G-L group and G-H group (G-L and G-H refer to a low or high dose of ginsenoside Rh2 injection) are reduced compared with the tumor group (P<0.05). The survival analysis reveals that the Ginsenoside Rh2 treated groups survive longer than the untreated tumor group and the effect is dose-dependent (P<0.05).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Ginsenoside Rh2 | HY-N0605 | HY N0605
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    EGFR
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    78214-33-2
  • Formula Weight
    622.87
  • Molecular Formula
    C36H62O8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 300 mg/mL; 481.64 mM
  • SMILES
    O[C@H]1[C@@H](O[C@@H]([C@H]([C@@H]1O)O)CO)O[C@@H]1C([C@H]2[C@@]([C@@H]3[C@]([C@]4([C@H]([C@@H](C3)O)[C@@H]([C@@](O)(CCC=C(C)C)C)CC4)C)(CC2)C)(CC1)C)(C)C
  • Chemical Name
    (2R,3R,4S,5S,6R)-2-(((3R,8R,9R,10R,12S,13R,14R,17S)-12-hydroxy-17-((S)-2-hydroxy-6-methylhept-5-en-2-yl)-4,4,8,10,14-pentamethylhexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Zhang H, et al. Int J Clin Exp Pathol. 2015 May 1;8(5):4444-56.
molnova catalog
related products
  • Ethyl 34-dihydroxybe...

    Ethyl?34-dihydroxybenzoate?(EDHB): a prolyl hydroxylase inhibitor attenuates acute hypobaric hypoxia mediated vascular leakage in brain.

  • [D-Ala2]-β-Casomorph...

    [D-Ala2]-β-Casomorphin (1-3) amide

  • Opicinumab

    Opicinumab (BIIB033) is a novel monoclonal antibody against LINGO-1 that may be used to prevent and delay acute optic neuritis and recurrent multiple sclerosis.